Long­time Zymeworks CEO, co-founder Tehrani hits the ex­it in fa­vor of se­r­i­al biotech en­tre­pre­neur

Af­ter a down year, bio­phar­ma writ large is look­ing for a breath of fresh air — and now the winds of change have hit on­col­o­gy bis­pecifics play­er Zymeworks.

Ali Tehrani, a co-founder of Zymeworks who has been the biotech’s CEO since 2003, has re­signed from his po­si­tion and will be re­placed by Ken Gal­braith, a se­r­i­al biotech en­tre­pre­neur and for­mer board mem­ber, the com­pa­ny said Wednes­day.

Tehrani will take on an ad­vi­so­ry role with the com­pa­ny once his tenure for­mal­ly ends Feb. 1 to help aid in the tran­si­tion for Gal­braith’s lead­er­ship turn. Mean­while, board chair Lota Zoth will be moved in­to an in­de­pen­dent di­rec­tor role in con­junc­tion with the shake­up.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN